Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“Follow MedCity News if you want to know who is doing what in healthcare innovation - and whether it's working or not.”

Chris Seper, CEO & Founder, MedCityNews.com


Sign up for our daily newsletter


Biotech startup adds Pfizer meningitis vaccine to product portfolio

December 10, 2012 8:34 pm by | 0 Comments

A biotechnology startup led by a Pfizer (NYSE:PFE) veteran has acquired a vaccine to guard against meningitis, sepsis and pneumonia.

The Meningitec vaccine, acquired from Pfizer for an undisclosed amount, will be used to help the company expand into new markets and combat bacterial diseases caused by Neisseria meningitidis, Richard Dinovitz, vice president for marketing and business development at Nuron Biotech, said in a statement.

Exton, Pennsylvania-based Nuron Biotech has been building a portfolio of vaccines from acquisitions and licensing agreements.

Last year, it added a Hib vaccination from Wyeth, owned by Pfizer. Hib bacteria used to be the most common bacterial meningitis, according to the Centers for Disease Control and Prevention, responsible for about 20,000 cases of Hib disease each year in the U.S. That was before the development of the Hib vaccine. Germs caused by the bacteria invade parts of the body that are normally free from germs and worsen the effects of the disease, and cause hospitalization or even death. Although it retains the license to market the vaccine in the U.S. and other markets, it inked a licensing agreement with Mitsubishi Tanabe earlier this year for the Japanese markets, for which it will receive significant royalties.

Advertisement

It also licensed an Alzheimer’s vaccine in the preclinical stage from Texas-based VITRUVIAN Biomedical in April. The amyloid beta vaccine uses a piece of the gene coding for the amyloid beta protein to stimulate an immune response. Antibodies attack and reduce the amyloid beta in the body that contribute to the plaque deposits in the brain that are associated with Alzheimer’s disease.

It also owns exclusive licenses for technology and product rights for hepatitis B and C, acquired from Canadian firm Akshaya Bio. An estimated 380 million people are infected with hepatitis B, for which there is no known cure. Phase 1 trials of the vaccine platform are slated for 2013.

 

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Stephanie Baum

By Stephanie Baum

Stephanie Baum is the East Coast Innovation Reporter for MedCityNews.com. She enjoys covering healthcare startups across health IT, drug development and medical devices and innovations deployed to improve medical care. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's written for The Christian Science Monitor, Dow Jones & Co. and United Business Media.
Visit website | More posts by Author

0 comments